These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 32980953)
1. Secondary failure of platelet recovery in patients treated with high-dose thiotepa and busulfan followed by autologous stem cell transplantation. Wada F; Nishikori M; Hishizawa M; Watanabe M; Aiba A; Kitano T; Shimazu Y; Shindo T; Kondo T; Takaori-Kondo A Int J Hematol; 2020 Nov; 112(5):609-613. PubMed ID: 32980953 [TBL] [Abstract][Full Text] [Related]
2. A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning. Scordo M; Bhatt V; Hsu M; Omuro AM; Matasar MJ; DeAngelis LM; Dahi PB; Moskowitz CH; Giralt SA; Sauter CS Biol Blood Marrow Transplant; 2017 Jan; 23(1):38-43. PubMed ID: 27713090 [TBL] [Abstract][Full Text] [Related]
3. Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Chen YB; Batchelor T; Li S; Hochberg E; Brezina M; Jones S; Del Rio C; Curtis M; Ballen KK; Barnes J; Chi AS; Dietrich J; Driscoll J; Gertsner ER; Hochberg F; LaCasce AS; McAfee SL; Spitzer TR; Nayak L; Armand P Cancer; 2015 Jan; 121(2):226-33. PubMed ID: 25204639 [TBL] [Abstract][Full Text] [Related]
4. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. DeFilipp Z; Li S; El-Jawahri A; Armand P; Nayak L; Wang N; Batchelor TT; Chen YB Cancer; 2017 Aug; 123(16):3073-3079. PubMed ID: 28369839 [TBL] [Abstract][Full Text] [Related]
5. Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant. Oh DH; Chua N; Street L; Stewart DA Leuk Lymphoma; 2016; 57(1):28-33. PubMed ID: 25747968 [TBL] [Abstract][Full Text] [Related]
6. Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma. Hyung J; Hong JY; Yoon DH; Kim S; Park JS; Park CS; Lee SW; Kim JH; Ryu JS; Huh J; Suh C Ann Hematol; 2019 Jul; 98(7):1657-1664. PubMed ID: 30989325 [TBL] [Abstract][Full Text] [Related]
8. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Lee JL; Gooley T; Bensinger W; Schiffman K; McDonald GB Biol Blood Marrow Transplant; 1999; 5(5):306-15. PubMed ID: 10534061 [TBL] [Abstract][Full Text] [Related]
9. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Ferreri AJ; Cwynarski K; Pulczynski E; Ponzoni M; Deckert M; Politi LS; Torri V; Fox CP; Rosée PL; Schorb E; Ambrosetti A; Roth A; Hemmaway C; Ferrari A; Linton KM; Rudà R; Binder M; Pukrop T; Balzarotti M; Fabbri A; Johnson P; Gørløv JS; Hess G; Panse J; Pisani F; Tucci A; Stilgenbauer S; Hertenstein B; Keller U; Krause SW; Levis A; Schmoll HJ; Cavalli F; Finke J; Reni M; Zucca E; Illerhaus G; Lancet Haematol; 2016 May; 3(5):e217-27. PubMed ID: 27132696 [TBL] [Abstract][Full Text] [Related]
10. Outcomes of Consecutively Diagnosed Primary Central Nervous System Lymphoma Patients Using the Alberta Lymphoma Clinical Practice Guideline Incorporating Thiotepa-Busulfan Conditioning for Transplantation-Eligible Patients. Sanders S; Chua N; Larouche JF; Owen C; Shafey M; Stewart DA Biol Blood Marrow Transplant; 2019 Aug; 25(8):1505-1510. PubMed ID: 30965138 [TBL] [Abstract][Full Text] [Related]
11. High pre-transplant serum ferritin and busulfan-thiotepa conditioning regimen as risk factors for hepatic sinusoidal obstructive syndrome after autologous stem cell transplantation in patients with malignant lymphoma. Hwang DY; Kim SJ; Cheong JW; Kim Y; Jang JE; Lee JY; Min YH; Yang WI; Kim JS Leuk Lymphoma; 2016; 57(1):51-7. PubMed ID: 25899401 [TBL] [Abstract][Full Text] [Related]
12. Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma. Grisariu S; Shapira MY; Or R; Avni B Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):272-279. PubMed ID: 29500148 [TBL] [Abstract][Full Text] [Related]
13. Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network. Schenone L; Houillier C; Tanguy ML; Choquet S; Agbetiafa K; Ghesquières H; Damaj G; Schmitt A; Bouabdallah K; Ahle G; Gressin R; Cornillon J; Houot R; Marolleau JP; Fornecker LM; Chinot O; Peyrade F; Bouabdallah R; Moluçon-Chabrot C; Gyan E; Chauchet A; Casasnovas O; Oberic L; Delwail V; Abraham J; Roland V; Waultier-Rascalou A; Willems L; Morschhauser F; Fabbro M; Ursu R; Thieblemont C; Jardin F; Tempescul A; Malaise D; Touitou V; Nichelli L; Le Garff-Tavernier M; Plessier A; Bourget P; Bonmati C; Wantz-Mézières S; Giordan Q; Dorvaux V; Charron C; Jabeur W; Hoang-Xuan K; Taillandier L; Soussain C; Bone Marrow Transplant; 2022 Jun; 57(6):966-974. PubMed ID: 35422077 [TBL] [Abstract][Full Text] [Related]
14. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study. Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830 [TBL] [Abstract][Full Text] [Related]
15. Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies. Weaver CH; Bensinger WI; Appelbaum FR; Lilleby K; Sandmaier B; Brunvand M; Rowley S; Petersdorf S; Rivkin S; Gooley T Bone Marrow Transplant; 1994 Nov; 14(5):813-9. PubMed ID: 7889015 [TBL] [Abstract][Full Text] [Related]
16. Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation. Scordo M; Morjaria SM; Littmann ER; Bhatia A; Chung HH; Maloy M; DeAngelis LM; Giralt SA; Taur Y; Sauter CS Biol Blood Marrow Transplant; 2018 Sep; 24(9):1914-1919. PubMed ID: 29679773 [TBL] [Abstract][Full Text] [Related]
17. Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas. Jo JC; Kim JS; Lee JH; Lee JH; Im SN; Lee SM; Yoon SS; Kim IH; Bae SH; Lee YJ; Choi Y; Lee WS Ann Hematol; 2021 Jan; 100(1):189-196. PubMed ID: 33205337 [TBL] [Abstract][Full Text] [Related]
18. Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant. Puckrin R; Chua N; Shafey M; Stewart DA Leuk Lymphoma; 2022 Oct; 63(10):2444-2452. PubMed ID: 35459424 [TBL] [Abstract][Full Text] [Related]
19. Retrospective analysis of high-dose chemotherapy followed by autologous stem cell transplantation for high-risk pediatric osteosarcoma. Uemura S; Mori T; Ishiko S; Takafuji S; Nino N; Yamamoto N; Hayakawa A; Nishimura N; Hara H; Kawamoto T; Akisue T; Iijima K Pediatr Hematol Oncol; 2020 May; 37(4):337-343. PubMed ID: 32151185 [TBL] [Abstract][Full Text] [Related]
20. Thiotepa, Busulfan, Cyclophosphamide: Effective but Toxic Conditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Central Nervous System Lymphoma. Delphine L; Pierre-Edouard D; Bruno R; Bérengère G; Magalie J; Patrick V; Jean-Pierre M; Pierre M Med Sci (Basel); 2023 Jan; 11(1):. PubMed ID: 36810481 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]